Cocrystal Pharma, Inc. - Common Stock (NQ:COCP)

0.9880 +0.0080 (+0.82%)

Delayed Quote Updated: 11:11 AM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cocrystal Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 07, 2023

Via Benzinga

Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket ↗

January 25, 2023

Gainers Inpixon (NASDAQ: INPX) shares rose 41% to $2.20 in pre-market trading after gaining 6% on Tuesday. Inpixon, last month, secured a purchase order valued at over $1m for its RTLS products from a...

Via Benzinga

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

January 23, 2023

Phoenix, Arizona--(Newsfile Corp. - January 23, 2023) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("Cocrystal," "Cocrystal...

Via Newsfile

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

December 01, 2022

From Cocrystal Pharma, Inc.

Via GlobeNewswire

Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate ↗

October 11, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

December 23, 2022

OnFriday, 143 stocks hit new 52-week lows.

Via Benzinga

Recap: Cocrystal Pharma Q2 Earnings ↗

August 15, 2022

Cocrystal Pharma (NASDAQ:COCP) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A ↗

November 17, 2022

Via Benzinga

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

November 17, 2022

From Cocrystal Pharma, Inc.

Via GlobeNewswire

Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs

November 14, 2022

From Cocrystal Pharma, Inc.

Via GlobeNewswire

Cocrystal Pharma to Participate in Two Investor Conferences in November

November 02, 2022

From Cocrystal Pharma, Inc.

Via GlobeNewswire

Recap: Cocrystal Pharma Q1 Earnings ↗

May 11, 2022

Cocrystal Pharma (NASDAQ:COCP) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday ↗

November 03, 2022

Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.

Via Benzinga

Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session ↗

November 02, 2022

Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.

Via Benzinga

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

November 01, 2022

From Cocrystal Pharma, Inc.

Via GlobeNewswire

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344

October 26, 2022

From Cocrystal Pharma, Inc.

Via GlobeNewswire

Cocrystal Pharma to Present at the LD Micro Main Event XV

October 19, 2022

From Cocrystal Pharma, Inc.

Via GlobeNewswire

Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022

October 13, 2022

From Cocrystal Pharma, Inc.

Via GlobeNewswire

Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19

October 11, 2022

From Cocrystal Pharma, Inc.

Via GlobeNewswire

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

October 05, 2022

From Cocrystal Pharma, Inc.

Via GlobeNewswire

Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday ↗

October 05, 2022

Losers

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

October 04, 2022

On Tuesday, 44 companies hit new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 04, 2022

Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million.

Via Benzinga

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

October 03, 2022

From Cocrystal Pharma, Inc.

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

August 17, 2022

We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning!

Via InvestorPlace

Why Hill International Shares Are Trading Higher By 58%: Here Are 25 Stocks Moving Premarket ↗

August 17, 2022

Gainers Hill International, Inc. (NYSE: HIL) shares rose 58.1% to $2.75 in pre-market trading after the company agreed to be acquired by Global Infrastructure Solutions Inc. for $2.85 per share.

Via Benzinga

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

August 03, 2022

Phoenix, Arizona--(Newsfile Corp. - August 3, 2022) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("the Company"),...

Via Newsfile

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 15, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 06, 2022

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million.

Via Benzinga

The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data ↗

April 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.